R&D Net Treatment Benefit in rare disease trials: Aligning trial... Net Treatment Benefit provides a formal framework to integrate multiple prioritised outcomes into a single measure of overall treatment effect.
R&D Sponsored Webinar recap: The future of cell and gene therapy in rare d... For decades, treatment options for rare diseases have been limited, often focusing on symptom management rather than addressing the root cause of them
R&D On a journey to diverse, inclusive, and more efficient rare ... Although orphan drugs represent a sizeable portion of new drug approvals,1most rare diseases still lack effective treatment.
Oncology Hernexeos and what’s next, with Vicky Brown At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.